Increased levels of long noncoding RNA LINC00691 correlate with poor prognosis in non-small-cell lung cancer patients.

BACKGROUND

Although long intergenic non-protein coding RNA 691 (LINC00691) has been functionally identified in several tumors, the association between LINC00691 and non-small-cell lung cancer (NSCLC) has not been reported. The objective of our study was to explore the clinical significance of LINC00691 in NSCLC.

METHODS

RT-PCR was performed to detect LINC00691 levels in 177 pairs of human NSCLC tissues and matched normal lung specimens. A chi-squared test was used to analyze the possible influence of LINC00691 on the clinical progress of NSCLC. Kaplan-Meier methods were used to determine differences in patient survival. The prognostic value of survival variables was evaluated using univariate and multivariate analyses.

RESULTS

We found that LINC00691 levels were increased in tumor specimens compared with matched normal lung tissues (P < .01). Increased LINC00691 levels correlated with lymph node metastasis (P = .025) and advanced TNM stage (P = .002) in NSCLC patients. Moreover, clinical investigations revealed that NSCLC patients with high LINC00691 expression had a shorter overall survival than those with low LINC00691 expression (P = .0042). Finally, Cox regression assays confirmed LINC00691 as an independent prognostic factor for NSCLC patients.

CONCLUSIONS

The aberrant expression of LINC00691 may function as a reliable marker for the progression and prognosis of NSCLC in patients.